IDEN BIOTECHNOLOGY SL

Their core work

IDEN Biotechnology is a Spanish agricultural biotechnology SME based in Navarre that develops biological and genetic solutions to improve crop performance and resilience. Their work covers two complementary tracks: formulating agrobiological products (microbial or biological inputs) that enhance crop yields sustainably, and applying CRISPR/Cas9 gene editing to engineer abiotic stress tolerance in cereal crops. Both directions address the same underlying business problem — making crops more productive and robust under environmental pressure — but from different technological entry points. They have operated as an independent R&D company, coordinating their own EU-funded feasibility projects rather than joining larger consortia.

What they specialise in

How they've shifted over time

IDEN's trajectory over their two H2020 projects shows a clear progression from biological agronomy toward molecular genetic engineering. Their first project (2015) was rooted in agrobiological product development — a field closer to conventional sustainable agriculture. By 2017, they had pivoted to CRISPR/Cas9 implementation, one of the most technically demanding areas in modern plant biotechnology. This is not a gradual drift but a deliberate step up in technological complexity, suggesting the company was actively building molecular biology capabilities during this period.

IDEN appears to be positioning itself at the gene editing end of agricultural biotech — a high-value, high-barrier space — which would make them a relevant partner for projects in precision breeding, climate-resilient crops, or EU regulatory work around new genomic techniques (NGTs).

How they like to work

IDEN has coordinated both of their H2020 projects independently, with no recorded consortium partners in either. This pattern is consistent with SME Instrument Phase 1 grants, which are designed for single-company feasibility studies rather than collaborative research. It means there is no evidence of how they perform inside a multi-partner consortium — they have operated as a standalone innovator rather than a network participant. A consortium builder considering IDEN should treat them as an untested consortium member and factor that in when assigning roles.

No consortium partner data is available for IDEN — both projects were solo-coordinated SME Instrument feasibility studies, which do not involve formal consortium structures. Their collaboration footprint within the EU research ecosystem is effectively zero in the recorded data.

What sets them apart

IDEN occupies an unusual dual position: they have hands-on experience with both biological agricultural inputs and CRISPR-based genetic engineering, which are typically the domain of very different types of companies. For a small Spanish SME, demonstrating CRISPR capability in cereals at the H2020 level is notable. This breadth — from soil biology to gene editing — makes them potentially useful in projects that need to compare or combine biological and genetic crop improvement strategies.

Highlights from their portfolio

• CRISP-4-CROPS
  Their highest-funded project (€72,500) and the technically most advanced — applying CRISPR/Cas9 to abiotic stress resistance in cereals, a topic now central to EU climate-resilient agriculture agendas.
• BIOAGRIBOOSTER
  Their founding H2020 project, demonstrating early competence in sustainable biological crop inputs at a time when the EU was shaping its Farm-to-Fork and bioeconomy strategies.